ImetelChat

From the recent article posted: “ Thus, we believe our data provide THE (emphasis mine) preclinical validation for clinical evaluation of imetelstat in pediatric AML.”

Pediatric AML seems to be very different from adult AML. Looking over the data from the recently posted study one can see that the while Imetelstat significantly reduced LSCs, the life of the experimental animals was only extended in time measured in days, even though clinically significant. The search for therapy to “debulk” non LSCs combined with therapy which attacks the LSC will probably provide the framework for a future study. Recall that Imetelstat also reduced myeloma stem cells it did not seem have a profound effect on the basic disease.